ClinicalTrials.gg
CompletedNCT06226090Updated May 14, 2025

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

A Phase 2 interventional study of TG103 7.5 mg and Placebo 7.5 mg in Obesity and Overweight, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
119th of 502
314 · median 120
Started
2024
with 76 others
Phase 2
52 of 600
17 open now
Registered
241st of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 119th largest by enrollment of the 502 interventional ones that give a count, is one of 77 that started in 2024, is one of 52 in phase 2, and was the 241st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, parallel phase 2 study to evaluate efficacy, safety, pharmacokinetic characteristics and immunogenicity of TG103 injection for weight management in non-diabetic patients with overweight in the presence of comorbidities or obesity, in addition to lifestyle intervention.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years ≤ age ≤ 75 years.
  • (BMI) ≥ 28 kg/m\^2, or 24 kg/m\^2 \< BMI ≤ 28 kg/m\^2 with at least one of obesity-related complications.
  • Regular diet and exercise and stable body weight (i.e., self-reported body weight change \< 5%) within 12 weeks before screening as well as body weight ≥ 60 kg at screening.
  • Weight loss less than 5% or no weight loss after diet and exercise intervention for at least 12 weeks.

Exclusion criteria

Exclusion Criteria:

  • History of type 2 diabetes, type 1 diabetes or hypoglycemia.
  • Overweight or obesity due to disease or drug; or weight increase due to non-fat mass increase; or monogenic obesity.
  • Medications or products which are judged by investigators to cause change in weight and influence trial evaluations have been used within 12 weeks before screening or will be used during study.
  • Weight loss less than 5% by monotherapy or combination with GLP-1 receptor agonists for at least 12 weeks before screening.
  • Bariatric surgery within 12 months before screening; or no full recovery from any surgery or injury at screening; or gastrointestinal motility dysfunction due to gastrointestinal surgery.
  • Participation in any clinical trial to receive treatment within 12 weeks before screening, or participation in clinical trial to receive TG103 before screening.
  • History of allergy or suspected allergy to GLP-1 receptor agonists or antibody agents, or suspected allergy to TG103 judged by investigator due to other severe allergy history.
  • Personal history or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2).
  • History or screening ultrasound reports of chronic pancreatitis, acute pancreatitis, etc.
  • History of severe gastrointestinal disease; or gastrointestinal symptom at screening; or discontinuation of GLP-1 receptor agonist, GLP-1/GIP receptor agonist, GLP-1/GCG receptor agonist or metformin due to gastrointestinal adverse reaction.
  • Severe infection at screening.
  • Skin disorder that influences safety evaluation at screening.
  • History of severe disease or malignant tumor.
  • Systolic blood pressure ≥ 160 mmHg, diastolic blood pressure ≥ 100 mmHg, Grade Ⅲ-Ⅳ, prolongation or severe arrhythmia at screening.
  • History of abnormal thyroid function with requirement of medication treatment at screening, or screening TSH beyond the normal reference range.
  • One of the followings at screening: 1) ≥ 6.5%, or FPG ≥ 7.0mmol/L or\<2.8mmol/L; 2) calcitonin ≥ 50 ng/L; 3) or AST>3 × UNL (upper normal limit), or total >1.5 × UNL; 4) blood amylase or lipase>1.5 × UNL, 5) TG>5.6mmol/L, 6) \<60ml/min/1.73m\^2 , 7) positive of , -antibody, -antibody or anti-TP antibody, 8) WBC\< 3×10\^9/L, or \<100g/L, 9) >1.2.
  • History of drug abuse, drug dependence or alcoholism.
  • History of moderate to severe depression, or screening Patient Health Questionaire-9 (PHQ-9) score ≥ 15.
  • The fertile female who is pregnant, breast-feeding or with blood HCG positive at screening; or the fertile participants and their partner cannot use an effective method during the trial and within 3 months after the end of treatment.
  • Other situations unsuitable for this study in the investigator\'s opinion.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    TG103 7.5 mg

    Drug: TG103 7.5 mg

  • Placebo comparator
    Placebo 7.5 mg

    Drug: Placebo 7.5 mg

  • Experimental
    TG103 15 mg

    Drug: TG103 15 mg

  • Placebo comparator
    Placebo 15 mg

    Drug: Placebo 15 mg

  • Experimental
    TG103 22.5 mg

    Drug: TG103 22.5 mg

  • Placebo comparator
    Placebo 22.5 mg

    Drug: Placebo 22.5 mg

Interventions

  • Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.

  • DrugPlacebo 7.5 mg

    Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.

  • Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

  • DrugPlacebo 15 mg

    Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

  • Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.

  • DrugPlacebo 22.5 mg

    Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.

06

What researchers measure

Primary outcomes

  1. Percentage relative change from baseline in body weight at week 24

    Time frame: From baseline to week 24

Secondary outcomes

  1. Proportion of participants with weight loss of ≥ 5% at week 24

    Time frame: From baseline to week 24

  2. Proportion of participants with weight loss of ≥ 10% at week 24

    Time frame: From baseline to week 24

  3. Change from baseline to week 24 in waist circumference

    Time frame: From baseline to week 24

  4. Relative change from baseline in body weight at week 24

    Time frame: From baseline to week 24

  5. Change from baseline to week 24 in systolic blood pressure

    Time frame: From baseline to week 24

  6. Change from baseline to week 24 in diastolic blood pressure

    Time frame: From baseline to week 24

  7. Title: Change from baseline to week 24 in serum total cholesterol

    Time frame: From baseline to week 24

  8. Title: Change from baseline to week 24 in serum triglyceride

    Time frame: From baseline to week 24

  9. Title: Change from baseline to week 24 in serum low density lipoprotein cholesterol

    Time frame: From baseline to week 24

  10. Title: Change from baseline to week 24 in serum high density lipoprotein cholesterol

    Time frame: From baseline to week 24

Other outcomes

  1. Number of TEAEs (Treatment Emergent Adverse Events) and SAEs (Serious Adverse Events)

    Time frame: From baseline to week 27

  2. Change from baseline to week 24 in serum calcitonin

    Time frame: From baseline to week 24

  3. Change from baseline to week 24 in serum alanine transaminase

    Time frame: From baseline to week 24

  4. Change from baseline to week 24 in serum creatinine

    Time frame: From baseline to week 24

  5. Change from baseline to week 24 in serum HCG (Human Chorionic Gonadotophin)

    Time frame: From baseline to week 24

  6. Plasma concentration of TG103

    Time frame: From baseline to week 27

  7. Number of patients with positive TG103 antibody

    Time frame: From baseline to week 27

07

Study locations

1 site
  • Clinical Trials Information Group
    Shijiazhuang, Hebei 050011, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Sep 2024, 7 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 7 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Jan 26, 2024
StartActual
Feb 21, 2024
Primary completionActual
Sep 26, 2024
CompletionActual
Oct 24, 2024
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06226090
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
Feb 21, 2024
Primary completion
Sep 26, 2024
Completion
Oct 24, 2024
Last update
May 14, 2025

Study contacts

Li Yan Study Principal Investigator
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG103

Start the discussion